Abstract
The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin receptors are common in cancer cells resulting in alteration of the ability of malignant cells to interact with the extracellular matrix, and promoting migration as well as facilitating survival outside the tumour normal environment. β integrins are potentially involved in every step of the metastatic process and expression of both αρ β and α β is correlated with metastatic ability of tumour cells. The recognition of the RGD binding motif common to the disintegrins and natural integrin ligands such as fibrinogen allowed the development of small molecule β integrin antagonists, progressing from linear peptides containing the RGD sequence to cyclic peptides with well-defined conformation, and hence to small molecule peptidomimetics with improved pharmacological properties. In this review, we summarize the role of the β -subfamily of integrins when expressed in normal and tumour tissue, the development of small-molecule antagonists of β integrins and their potential anti-cancer applications.
Keywords: β, integrin, cancer, metastasis, RGD peptidomimetic
Current Cancer Drug Targets
Title: Function and Antagonism of β Integrins in the Development of Cancer Therapy
Volume: 9 Issue: 4
Author(s): H. M. Sheldrake and L. H. Patterson
Affiliation:
Keywords: β, integrin, cancer, metastasis, RGD peptidomimetic
Abstract: The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin receptors are common in cancer cells resulting in alteration of the ability of malignant cells to interact with the extracellular matrix, and promoting migration as well as facilitating survival outside the tumour normal environment. β integrins are potentially involved in every step of the metastatic process and expression of both αρ β and α β is correlated with metastatic ability of tumour cells. The recognition of the RGD binding motif common to the disintegrins and natural integrin ligands such as fibrinogen allowed the development of small molecule β integrin antagonists, progressing from linear peptides containing the RGD sequence to cyclic peptides with well-defined conformation, and hence to small molecule peptidomimetics with improved pharmacological properties. In this review, we summarize the role of the β -subfamily of integrins when expressed in normal and tumour tissue, the development of small-molecule antagonists of β integrins and their potential anti-cancer applications.
Export Options
About this article
Cite this article as:
Sheldrake M. H. and Patterson H. L., Function and Antagonism of β Integrins in the Development of Cancer Therapy, Current Cancer Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/156800909788486713
DOI https://dx.doi.org/10.2174/156800909788486713 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Natural Compounds on Xenopus Embryogenesis: A Potential Read Out for Functional Drug Discovery Targeting Wnt/β-catenin Signaling
Current Topics in Medicinal Chemistry Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry Nanoparticles for Improved Therapeutics and Imaging in Cancer Therapy
Recent Patents on Nanotechnology Meet Our Editorial Board Member
Current Protein & Peptide Science Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry β2-AR-HIF-1α: A Novel Regulatory Axis for Stress-Induced Pancreatic Tumor Growth and Angiogenesis
Current Molecular Medicine STAT-1 and STAT-3: Closely Related Transcription Factors with Antagonistic Effects on Cell Proliferation and Apoptosis
Current Genomics Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Rational Design and Optimization of Trypsin Inhibitory Peptides with Antibacterial Activity
Current Computer-Aided Drug Design Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery Tissue-Specific Methylation of Long Interspersed Nucleotide Element-1 of Homo Sapiens (L1Hs) During Human Embryogenesis and Roles in Neural Tube Defects
Current Molecular Medicine Regulation by IFN-α/IFN-γ Co-Formulation (HerberPAG<sup>®</sup>) of Genes Involved in Interferon-STAT-Pathways and Apoptosis in U87MG
Current Topics in Medicinal Chemistry The Protein Acetyltransferase ARD1: A Novel Cancer Drug Target?
Current Cancer Drug Targets Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Comparative Proteomics of Liver of the Diabetic Obese db/db and Non-Obese or Diabetic Mice
Current Proteomics The Role of E-Cadherin Down-Regulation in Oral Cancer: CDH1 Gene Expression and Epigenetic Blockage
Current Cancer Drug Targets Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Current Molecular Medicine Hydrogen Sulfide-Based Anti-Inflammatory and Chemopreventive Therapies: An Experimental Approach
Current Pharmaceutical Design Microcantilever Biosensors: Probing Biomolecular Interactions at the Nanoscale
Current Organic Chemistry Glyconanoparticles for Biomedical Applications
Combinatorial Chemistry & High Throughput Screening